Podium Presentations
Monday, May 18, 2015
2:15 PM - 3:15 PM
RESEARCH PODIUM PRESENTATIONS - SESSION I

2:15 PM - 3:15 PM
Room: Grand Ballroom, Salon G (Level 5)
CV: CARDIOVASCULAR DISEASE RESEARCH STUDIES

CV1

2:15 PM - 2:30 PM

LIFETIME HEALTH CARE COSTS OF OBESITY-RELATED COMORBIDITIES IN THE UNITED STATES, 2007-2010

Chang S, Leung MY, Carlsson NP, Colditz GA
Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, St. Louis, MO, USA

CV2

2:30 PM - 2:45 PM

THE ASSOCIATION BETWEEN ADHERENCE TO CARDIOVASCULAR MEDICATIONS AND HEALTH CARE UTILIZATION

Simon-Tuval T1, Triki N2, Chodick G3, Greenberg D1
1Ben-Gurion University of the Negev, Beer-Sheva, Israel, 2Maccabi Healthcare Services, Tel-Aviv, Israel, 3Maccabi Healthcare Services and Tel-Aviv University, Tel-Aviv, Israel

CV3

2:45 PM - 3:00 PM

PREVALENCE AND DIRECT MEDICAL COSTS ASSOCIATED WITH ANGINA AND CHEST PAIN FOLLOWING PERCUTANEOUS CORONARY INTERVENTION IN THE UNITED STATES

Machacz S1, Bonafede MM2, Wade S3, Stephens L1, Hernandez J1
1Abbott Vascular, Santa Clara, CA, USA, 2Truven Health Analytics, Cambridge, MA, USA, 3Wade Outcomes Research and Consulting, Salt Lake City, UT, USA

CV4

3:00 PM - 3:15 PM

OUTCOMES AND HEALTH RESOURCE UTILIZATION AMONG PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) AT AN ACADEMIC MEDICAL CENTER (AMC) IN THE UNITED STATES

Bress A1, King J1, Singhal M1, Brixner D2, Kielhorn A3, Patel H3, Maya J3, Biskupiak JE1, Munger M1
1University of Utah, Salt Lake City, UT, USA, 2University of Utah, Pharmacotherapy Outcomes Research Center, Program in Personalized Health, Salt Lake City, UT, USA, 3Amgen, Thousand Oaks, CA, USA

2:15 PM - 3:15 PM
Room: Grand Ballroom, Salon K-L (Level 5)
DB: RESEARCH ON DATABASE METHODS STUDIES

DB1

2:15 PM - 2:30 PM

CRITICAL PROBLEMS OF CODING DATA IN HEALTH CARE: OBESITY, SMOKING, AND ALCOHOL USE BY METHOD OF MEASUREMENT

Al Kazzi ES1, Lau B1, Li T2, Schneider EB1, Makary MA1, Hutfless S1
1Johns Hopkins University School of Medicine, Baltimore, MD, USA, 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

DB2

2:30 PM - 2:45 PM

A NEW METHOD FOR COUNTING HEMOPHILIA-RELATED BLEEDING EVENTS IN CLAIMS DATA

Shrestha A1, Eldar-Lissai A2, Wu Y1, Batt K3, Krishnan S2, Lakdawalla D4
1Precision Health Economics, Los Angeles, CA, USA, 2Biogen Idec, Cambridge, MA, USA, 3Wake Forest School of Medicine, Winston-Salem, NC, USA, 4University of Southern California, Los Angeles, CA, USA

DB3

2:45 PM - 3:00 PM

THE IMPLICATIONS OF USING A 30-, 60-, OR 90-DAY GAP IN TREATMENT TO SPECIFY LINES OF CARE IN GASTRIC CANCER TREATMENT

Seal B1, Shermock KM2, Asche CV3, Kreilick C1, Xia F1, Kish J4, Zagadailov EA4, Eaddy M4
1Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA, 2The Johns Hopkins Medical Institutions, Baltimore, MD, USA, 3University of Illinois College of Medicine at Peoria, Peoria, IL, USA, 4Xcenda, Palm Harbor, FL, USA

DB4

3:00 PM - 3:15 PM

DEVELOPMENT AND VALIDATION OF ALGORITHMS TO IDENTIFY STATIN INTOLERANCE IN A US ADMINISTRATIVE DATABASE

Foody JM1, Lamerato L2, Dalal M3, Sung JC3, Khan I4, Jhaveri M3, Koren A3, Schulman KL5
1Harvard Medical School, Boston, MA, USA, 2Henry Ford Health System, Detroit, MI, USA, 3Sanofi US, Inc., Bridgewater, NJ, USA, 4Sanofi, Bridgewater, NJ, USA, 5Outcomes Research Solutions, Inc., Bolton, MA, USA

2:15 PM - 3:15 PM
Room: Grand Ballroom, Salon H (Level 5)
HM: HEALTH CARE MANAGEMENT STUDIES

HM1

2:15 PM - 2:30 PM

UTILIZATION OF ANTIDIABETICS AFTER FDA SAFETY ANNOUNCEMENTS

Ding Y1, Gascue L1, Lu Y2, Ning N1, Joyce G1
1University of Southern California, Los Angeles, CA, USA, 2Harbor-UCLA Medical Center, Torrance, CA, USA

HM2

2:30 PM - 2:45 PM

DIFFERENCES IN MASTECTOMY RATES BASED ON HORMONE RECEPTOR STATUS IN EARLY STAGE TUMORS: A SEER DATABASE ANALYSIS

Hinyard L, Schwartz T
Saint Louis University, St. Louis, MO, USA

HM3

2:45 PM - 3:00 PM

A REVIEW OF THE LITERATURE REGARDING BIOSIMILARS: WHAT IS THE EVIDENCE FOR EQUIVALENCE?

Raisch DW1, Chen C1, Tuenter H2, Bennett C3, IJzerman MJ2
1University of New Mexico College of Pharmacy, Albuquerque, NM, USA, 2University of Twente, Enschede, The Netherlands, 3University of South Carolina College of Pharmacy, Columbia, SC, USA

HM4

3:00 PM - 3:15 PM

HOW MUCH EVIDENCE DO WE NEED BEFORE IMPLEMENTING PHARMACOGENOMIC TESTING IN THE CLINIC?

Guzauskas GF, Serbin M, Veenstra DL
University of Washington, Seattle, WA, USA

2:15 PM - 3:15 PM
Room: Grand Ballroom, Salon C, D, E (Level 5)
MA: MEDICATION ADHERENCE STUDIES

MA1

2:15 PM - 2:30 PM

IMPACT OF A PHARMACIST MEDICATION ADHERENCE CONSULTATION PROGRAM ON HEALTH CARE COSTS AND RISK OF HOSPITALIZATION

Wade RL1, Hill JW1, Akinbosoye O2, Jiang Z2, Mu Y2, Sun K1, Karkare S3, Taitel MS2
1IMS Health, Plymouth Meeting, PA, USA, 2Walgreen Co., Deerfield, IL, USA, 3IMS Health, Deerfield, IL, USA

MA2

2:30 PM - 2:45 PM

COST OF NON-ADHERENCE TO MEDICATION IN A POST-MI POPULATION

Garrido E1, Arnold RJ1, Bansilal S2, Castellano JM2, Wei HG3, Freeman A4, Garcia-Alonso F5, Espinosa C6, Lizano I6, Spettell C4, Steinberg G3, Fuster V2
1Icahn School of Medicine at Mount Sinai, New York, NY, USA, 2The Mount Sinai Medical Center, New York, NY, USA, 3Aetna, New York, NY, USA, 4Aetna, Data Science, Hartford, CT, USA, 5Ferrer internacional, Barcelona, Spain, 6Ferrer, Barcelona, Spain

MA3

2:45 PM - 3:00 PM

THE EFFECT OF COST-RELATED MEDICATION NONADHERENCE ON THE DECISION OF TAKING UP MEDICARE PART D AMONG ELDERLY MEDICARE BENEFICIARIES

Han Y, Balkrishnan R
University of Michigan, Ann Arbor, MI, USA

MA4

3:00 PM - 3:15 PM

COMPREHENSIVE ASSESSMENT OF PATIENT ADHERENCE TO DRUG THERAPY: AN EXAMPLE UTILIZING REAL WORLD DATA FOR AN ORAL MULTIPLE SCLEROSIS TREATMENT

Irwin DE1, Cappell KA2, Davis BM2, Wu Y3, Grinspan A4, Gandhi SK3
1Truven Health Analytics, Chapel Hill, NC, USA, 2Truven Health Analytics, Ann Arbor, MI, USA, 3TEVA Pharmaceuticals, Frazer, PA, USA, 4Teva Pharmaceuticals, Weston, FL, USA

2:15 PM - 3:15 PM
Room: Grand Ballroom, Salon I (Level 5)
MD: MEDICAL DEVICE & DIAGNOSTIC RESEARCH STUDIES

MD1

2:15 PM - 2:30 PM

ECONOMIC EVALUATION OF BST-CARGEL AS AN ADJUNCT TO MICROFRACTURE VERSUS MICROFRACTURE ALONE IN KNEE CARTILAGE SURGERY

Frappier J
Data 4 Actions, Blainville, QC, Canada

MD2

2:30 PM - 2:45 PM

COVERAGE LIMITS ON BLOOD GLUCOSE TEST STRIP REIMBURSEMENT FOR DIABETICS IN CANADA: UTILIZATION IMPACT FOR DIABETIC PATIENTS IN THE ONTARIO PUBLIC DRUG PROGRAM (OPDP)

Bosnic N1, Goodfield JM2, Robertson CM2, Zhang Y1
1IMS Brogan, Kanata, ON, Canada, 2IMS Brogan, Mississauga, ON, Canada

MD3

2:45 PM - 3:00 PM

ECONOMIC IMPACT OF CHANGES IN NICU VENTILATION STRATEGIES WITH THE ADVENT OF NEW NONINVASIVE VENTILATION TECHNIQUES: A REVIEW AND PROPOSED ASSESSMENT FRAMEWORK FOR HIGH FLOW THERAPY (HFT) AS A ROUTINE RESPIRATORY SUPPORT PARADIGM

Pietzsch JB1, Garner AM1, McQueen MC2
1Wing Tech Inc., Menlo Park, CA, USA, 2Banner Thunderbird Medical Center, Glendale, AZ, USA

MD4

3:00 PM - 3:15 PM

ECONOMIC VALUE OF IMPROVED ACCURACY FOR SELF-MONITORING OF BLOOD GLUCOSE DEVICES FOR TYPE 1 DIABETES

McQueen RB1, Breton M2, Ott M3, Koa H4, Beamer B4, Campbell JD1
1University of Colorado Anschutz Medical Campus, Denver, CO, USA, 2University of Virginia Health System, Charlottesville, CO, USA, 3Bayer HealthCare, Leverkusen, Germany, 4Bayer HealthCare, Etobicoke, ON, Canada

2:15 PM - 3:15 PM
Room: Grand Ballroom, Salon A, B, F (Level 5)
MO: RESEARCH ON MODELING METHODS STUDIES

MO1

2:15 PM - 2:30 PM

REDUCING AND QUANTIFYING OVER-FITTING IN REGRESSION MODELS

Rigg J, Hankins M
IMS Health, London, UK

MO2

2:30 PM - 2:45 PM

A COMPARISON OF STATE TRANSITION AND DISCRETE EVENT MODELING APPROACHES FOR ANTIPLATELET USE IN THE SECONDARY PREVENTION OF THROMBOTIC EVENTS AFTER MYOCARDIAL INFARCTION (MI)

Ozer-Stillman I1, Whalen JD2, Bash LD3, Du M1, Oguz M1, Singhal PK4, Davies GM4
1Evidera, Lexington, MA, USA, 2Evidera, London, UK, 3Merck and Co., Inc., Rahway, NJ, USA, 4Merck and Co., Inc., North Wales, PA, USA

MO3

2:45 PM - 3:00 PM

DOES THE USE OF EFFICACY OR EFFECTIVENESS EVIDENCE IN COST-EFFECTIVENESS ANALYSES MATTER?

Dilokthornsakul P1, Chaiyakunapruk N2, Campbell JD3
1Center of Pharmaceutical Outcomes Research , Naresuan University, Muang, Phitsanulok, Thailand, 2Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Selangor, Malaysia, 3University of Colorado Anschutz Medical Campus, Denver, CO, USA

MO4

3:00 PM - 3:15 PM

EXTRAPOLATING ALL-CAUSE MORTALITY ESTIMATES IN ECONOMIC EVALUATIONS: A SIMULATION ANALYSIS

Pechlivanoglou P1, Abrahamyan L2, Paulden M3, Pham B4, Krahn MD4
1THETA (Toronto Health Economics and Technology Assessment Collaborative), Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3University of Alberta, Edmonton, AB, Canada, 4Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada
3:45 PM - 4:45 PM
RESEARCH PODIUM PRESENTATIONS - SESSION II

3:45 PM - 4:45 PM
Room: Grand Ballroom, Salon A, B, F (Level 5)
CN: CANCER OUTCOMES RESEARCH STUDIES

CN1

3:45 PM - 4:00 PM

THE IMPACT OF CHRONIC CONDITIONS ON THE ECONOMIC BURDEN OF CANCER SURVIVORSHIP IN THE UNITED STATES

Guy G1, Ekwueme D2, Li R1, Rim SH1, Yabroff KR3
1Centers for Disease Control and Prevention, Atlanta, GA, USA, 2Centers for Disease Control and Prevention, Chamblee, GA, USA, 3National Cancer Institute, Rockville, MD, USA

CN2

4:00 PM - 4:15 PM

A COMPARATIVE COST UTILITY ANALYSIS FOR FIRST LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS

Carlson JJ1, Slejko JF2, Goertz H3, Veenstra DL1
1University of Washington, Seattle, WA, USA, 2University of Maryland, Baltimore, MD, USA, 3Genentech, South San Francisco, CA, USA

CN3

4:15 PM - 4:30 PM

SYNTHESIS OF MULTIPLE TYPES OF SURVIVAL DATA WITHIN A WEIBULL PROPORTIONAL HAZARDS META-ANALYSIS: TREATMENT OUTCOMES IN PATIENTS WITH DOUBLE HIT LYMPHOMA (DHL)

Snedecor SJ1, Howlett C2, Mato A3
1Pharmerit International, Bethesda, MD, USA, 2Rutgers, The State University of New Jersey, Piscataway, NJ, USA, 3University of Pennsylvania, Philadelphia, PA, USA

CN4

4:30 PM - 4:45 PM

REIMBURSEMENT DECISION LANDSCAPE FOR METASTATIC BREAST CANCER THERAPIES: A COMPARISON OF FACTORS LEADING TO FAVORABLE AND UNFAVORABLE RECOMMENDATIONS ACROSS LEADING HTA AGENCIES

Banerjee P, Gupta J, Kumar P, Kapoor A, Mazumder D
Optum Global Solutions, Noida, India

3:45 PM - 4:45 PM
Room: Grand Ballroom, Salon I (Level 5)
CP: CONCEPTUAL PAPERS

CP1

3:45 PM - 4:00 PM

METHODS TO ASSESS THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES AND CLINICAL ENDPOINTS

Odom D, McLeod L, Sherif B, Nelson L
RTI Health Solutions, Research Triangle Park, NC, USA

CP2

4:00 PM - 4:15 PM

INTERVENTIONS FOR ULTRA-RARE DISORDERS (URDS) AND THE LOGIC OF COST EFFECTIVENESS

Schlander M1, Garattini S2, Holm S3, Kolominsky-Rabas P4, Marshall DA5, Nord E6, Persson U7, Postma M8, Richardson J9, Simoens S10, de Sola-Morales O11, Tolley K12, Toumi M13
1University of Heidelberg, Wiesbaden, Germany, 2Mario Negri Institute for Pharmacological Research, Milano, Italy, 3University of Manchester, Manchester, UK, 4Centre for Health Technology Assessment (HTA) and Public Health (IZPH), Friedrich-Alexander-University of Erlangen-Nürnberg; National Leading-Edge Cluster Medical Technologies ‘Medical Valley EMN’, Erlangen, Germany, 5Alberta Bone and Joint Health Institute, Calgary, AB, Canada, 6Norwegian Institute of Public Health, Oslo, Norway, 7The Swedish Institute for Health Economics (IHE), Lund, Sweden, 8University of Groningen, Groningen, The Netherlands, 9Monash University, Clayton, Victoria, Australia, 10KU Leuven, Leuven, Belgium, 11Sabirmedical, Barcelona, Spain, 12Tolley Health Economics Ltd., Buxton, Derbyshire, UK, 13Université Aix Marseilles, Marseilles, France

CP3

4:15 PM - 4:30 PM

LIFE AT A PREMIUM: CONSIDERING AN END-OF-LIFE PREMIUM IN VALUE-BASED REIMBURSEMENT

McCabe C1, Paulden M1, O'Mahony JF2, Edlin R3, Culyer AJ4
1University of Alberta, Edmonton, AB, Canada, 2Trinity College Dublin, Dublin, Ireland, 3University of Auckland, Auckland, New Zealand, 4University of Toronto, Toronto, ON, Canada

CP4

4:30 PM - 4:45 PM

GUIDANCE FOR THE CONDUCT AND REPORTING OF MODELING AND SIMULATION IN THE CONTEXT OF HEALTH TECHNOLOGY ASSESSMENT

Dahabreh I1, Balk E1, Wong JB2, Trikalinos TA1
1Brown University, Providence, RI, USA, 2Tufts Medical Center/Tufts University School of Medicine, Boston, MA, USA

3:45 PM - 4:45 PM
Room: Grand Ballroom, Salon H (Level 5)
CS: RESEARCH ON COST STUDIES METHODS

CS1

3:45 PM - 4:00 PM

US BASED DRUG COST PARAMETER ESTIMATES USING NATIONAL AVERAGE DRUG ACQUISITION COST

Levy JF, Rosenberg MA, Vanness DJ
University of Wisconsin-Madison, Madison, WI, USA

CS2

4:00 PM - 4:15 PM

ECONOMIC MODELLING IN RANDOMIZED CONTROLLED TRIAL (RCT)-BASED ECONOMIC EVALUATIONS: EMPIRICAL EXAMPLES OF ITS EFFECT ON THE PRECISION OF ECONOMIC AND DECISION OUTCOMES

Nam J, Berry C, Henderson R, Briggs A
University of Glasgow, Glasgow, UK

CS3

4:15 PM - 4:30 PM

CURE MODELS: ACCOUNTING FOR CURED PATIENTS IN ECONOMIC EVALUATIONS

Othus M1, Bansal A2, Koepl L1, Wagner S3, Ramsey S1
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 2University of Washington, Seattle, WA, USA, 3Bristol-Myers Squibb, Washington Crossing, PA, USA

CS4

4:30 PM - 4:45 PM

A REVIEW AND UPDATE TO THE GUIDANCE DOCUMENT FOR THE COSTING PROCESS IN THE CANADIAN HEALTH CARE SETTING

Budden AJ1, Lee K1, Jacobs P2
1CADTH, Ottawa, ON, Canada, 2Institute of Health Economics, Edmonton, AB, Canada

3:45 PM - 4:45 PM
Room: Grand Ballroom, Salon C, D, E (Level 5)
HE: HEALTH CARE EXPENDITURE STUDIES

HE1

3:45 PM - 4:00 PM

HEALTH CARE RESOURCE UTILIZATION AMONG MEDICARE BENEFICIARIES WITH COPD: COMPARISON OF HIGH AND LOW UTILIZERS

Xu X, Rao Y, Miyasato G
Trinity Partners, LLC, Waltham, MA, USA

HE2

4:00 PM - 4:15 PM

EXPLAINING THE EXCESS HOME HEALTH CARE USE AND EXPENDITURES AMONG ELDERLY MEDICARE BENEFICIARIES WITH PARKINSON'S DISEASE

Bhattacharjee S1, Metzger A2, Tworek C1, Wei W3, Pan X4, Sambamoorthi U2
1The University of Arizona, Tucson, AZ, USA, 2West Virginia University, Morgantown, WV, USA, 3Sanofi US LLC, Bridgewaters, NJ, USA, 4Evidera LLC, Lexington, MA, USA

HE3

4:15 PM - 4:30 PM

LONG-TERM HEALTH CARE COSTS AMONG ADULTS WITH TYPE 2 DIABETES INITIATING DPP-4 INHIBITORS

Farr AM1, Sheehan J2, Brouillette M1, Smith DM1, Johnston S1, Kalsekar I3
1Truven Health Analytics, Bethesda, MD, USA, 2AstraZeneca, Fort Washington, PA, USA, 3AstraZeneca, Wilmington, DE, USA

HE4

4:30 PM - 4:45 PM

OPTIMIZING CANCER CLINICAL TRIALS RESEARCH INVESTMENT DECISIONS IN THE UNITED STATES: A PROOF OF CONCEPT PORTFOLIO MANAGEMENT EVALUATION

Bennette CS1, Roth JA2, Basu A1, Carlson JJ1, Ramsey S2, Veenstra DL1
1University of Washington, Seattle, WA, USA, 2Fred Hutchinson Cancer Research Center, Seattle, WA, USA

3:45 PM - 4:45 PM
Room: Grand Ballroom, Salon G (Level 5)
HT: HEALTH TECHNOLOGY ASSESSMENT STUDIES

HT1

3:45 PM - 4:00 PM

SYSTEMATIC REVIEW OF COST EFFECTIVENESS OF ULTRA-ORPHAN THERAPIES: LESSON LEARNED FROM PUBLISHED HTAS AND STUDIES

Aggarwal S1, Topaloglu H1, Kumar S2
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, USA

HT2

4:00 PM - 4:15 PM

APPLICATION OF COST-EFFECTIVENESS LOGIC TO US MANAGED CARE DRUG FORMULARIES: LONG TERM OUTCOMES OF A VALUE-BASED FORMULARY

Yeung K1, Basu A2, Hansen RN1, Watkins J3, Sullivan SD2
1School of Pharmacy, University of Washington, Seattle, WA, USA, 2University of Washington, Seattle, WA, USA, 3Premera Blue Cross, Mountlake Terrace, WA, USA

HT3

4:15 PM - 4:30 PM

ANALYSIS OF NICE DRUG TECHNOLOGY APPRAISALS (2001-SEPTEMBER 2014)

Briceno V, Seoane-Vazquez E
MCPHS University, Boston, MA, USA

HT4

4:30 PM - 4:45 PM

IQWIG EARLY BENEFIT ASSESSMENTS OF TYPE 2 DIABETES THERAPIES

Oehrlein EM, Hanna ML, Perfetto EM
University of Maryland, School of Pharmacy, Baltimore, MD, USA

3:45 PM - 4:45 PM
Room: Grand Ballroom, Salon K-L (Level 5)
PP: PATIENT PREFERENCE STUDIES

PP1

3:45 PM - 4:00 PM

PATIENTS' AND PHYSICIANS' TIME TRADE-OFF PREFERENCES FOR ADVERSE OUTCOMES ASSOCIATED WITH METASTATIC COLORECTAL CANCER TREATMENTS

Morlock R1, Gonzalez JM2, Ogale S1, Sommer N1, Posner J2, Grothey A3
1Genentech, South San Francisco, CA, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3Mayo, Rochester, MN, USA

PP2

4:00 PM - 4:15 PM

PATIENT PREFERENCES FOR FIRST-LINE MAINTENANCE TREATMENTS FOR OVARIAN CANCER

Mansfield CA1, Poulos C1, Hackshaw MD2, Pugh A1, Jobanputra MH2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2GlaxoSmithKline, Philadelphia, PA, USA

PP3

4:15 PM - 4:30 PM

PATIENT VERSUS GENERAL POPULATION PREFERENCES IN ANTICOAGULANT THERAPY

Najafzadeh M, Gagne JJ, Choudhry NK, Polinski J, Avorn JL, Schneeweiss S
Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

PP4

4:30 PM - 4:45 PM

MEASURING TREATMENT PREFERENCES OF PATIENTS DIAGNOSED WITH IDIOPATHIC PULMONARY FIBROSIS USING BEST-WORST SCALING

Camponeschi GF1, Bridges JF2, Danoff SK1, Richardson B1
1Johns Hopkins University, Baltimore, MD, USA, 2John Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.